Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | CDC7 | O00311 | 5/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958476 | 0.85 | ALDH1A1 (0.50) | CYP19A1CDC7DBF4ALDH1A1CYP3A4 | |
| SCHEMBL6640643 | 0.83 | CPB2 (0.46) | CYP19A1CDC7DBF4ALDH1A1NAMPT | |
| SCHEMBL2672559 | 0.83 | MMP8 (0.54) | CYP19A1CDC7DBF4ALDH1A1NAMPT | |
| SCHEMBL27231825 | 0.83 | CYP19A1 (0.42) | CYP19A1CDC7DBF4ALDH1A1CYP3A4 | |
| SCHEMBL27231867 | 0.82 | CYP19A1 (0.44) | CYP19A1CDC7DBF4ALDH1A1CYP3A4 | |
| SCHEMBL2370955 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPK1GAAKMT2A | |
| SCHEMBL5314193 | 0.81 | CYP1A2 (0.48) | CYP19A1CDC7DBF4ALDH1A1CYP3A4 | |
| SCHEMBL27231720 | 0.80 | EPHX2 (0.52) | CYP19A1CDC7DBF4NAMPTKMT2A | |
| SCHEMBL6497419 | 0.80 | CYP19A1 (0.42) | CYP19A1CDC7DBF4ALDH1A1CYP3A4 | |
| SCHEMBL971944 | 0.79 | MMP8 (0.50) | CYP19A1CDC7DBF4ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| EP-2545037-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110612-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | CYP19A1 1236/4885CDC7 114/4885DBF4 3397/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | CYP19A1 1236/4885CDC7 114/4885DBF4 3397/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | CYP19A1 1236/4885CDC7 114/4885DBF4 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.